Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorIcoz, Kutay
dc.contributor.authorAkar, Unal
dc.contributor.authorUnal, Ekrem
dc.date.accessioned2021-01-27T09:41:08Z
dc.date.available2021-01-27T09:41:08Z
dc.date.issued2020en_US
dc.identifier.issn1387-2176
dc.identifier.issn1572-8781
dc.identifier.otherPubMed ID: 32661698
dc.identifier.urihttps://doi.org/10.1007/s10544-020-00503-6
dc.identifier.urihttps://hdl.handle.net/20.500.12573/506
dc.descriptionAuthors acknowledge TUBITAK (Project No: 115E020) for financial support. Authors also give thanks to Nazendenur Aksit and Ahsen Aydin for helping on taking the SEM images, Dr. Cengiz Gazeloglu from Isparta Suleyman Demirel University for valuable discussions on statistical analysis.en_US
dc.description.abstractWe report a time and cost-efficient microfluidic chip for screening the leukemia cells having three specific antigens. In this method, the target blast cells are double sorted with immunomagnetic beads and captured by the 3rd antibody immobilized on the gold surface in a microfluidic chip. The captured blast cells in the chip were imaged using a bright-field optical microscope and images were analyzed to quantify the cells. First sorting was performed with nano size immunomagnetic beads and followed by 2nd sorting where micron size immunomagnetic beads were used. The low-cost microfluidic platform is made of PMMA and glass including micro size gold pads. The developed microfluidic platform was optimized with cultured B type lymphoblast cells and tested with the samples of leukemia patients. The 8 bone marrow samples of 4 leukemia patients on the initial diagnosis and on the 15th day after the start of the chemotherapy treatment were tested both with the developed microfluidic platform and the flow cytometry. A 99% statistical agreement between the two methods shows that the microfluidic chip is able to monitor the decrease in the number of blast cells due to the chemotherapy. The experiments with the patient samples demonstrate that the developed system can perform relative measurements and have a potential to monitor the patient response to the applied therapy and to enable personalized dose adjustment.en_US
dc.description.sponsorshipTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) 115E020en_US
dc.language.isoengen_US
dc.publisherSPRINGER, VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDSen_US
dc.relation.isversionof10.1007/s10544-020-00503-6en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcomparative responseen_US
dc.subjectMicrofluidic -based monitoringen_US
dc.subjectDirect triple antibodyen_US
dc.subjectLeukemiaen_US
dc.subjectBiochipen_US
dc.subjectImmunoassayen_US
dc.subjectnano particlesen_US
dc.subjectMagnetic microen_US
dc.titleMicrofluidic Chip based direct triple antibody immunoassay for monitoring patient comparative response to leukemia treatmenten_US
dc.typearticleen_US
dc.contributor.departmentAGÜ, Mühendislik Fakültesi, Elektrik - Elektronik Mühendisliği Bölümüen_US
dc.contributor.authorID0000-0002-0947-6166en_US
dc.contributor.authorID0000-0002-0000-8999en_US
dc.identifier.volumeVolume: 22en_US
dc.identifier.issue3en_US
dc.relation.journalBIOMEDICAL MICRODEVICESen_US
dc.relation.tubitak115E020
dc.relation.publicationcategoryMakale - Uluslararası - Editör Denetimli Dergien_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster